APEX2 Mitochondrial Matrix Labeling for Proteomic Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing mitochondrial proteomes are limited by contamination with cytoplasmic proteins and inability to accurately determine protein location within mitochondria, leading to mixed experimental data and incomplete understanding of mitochondrial protein associations with diseases.
Innovation Solution
A transgenic animal specifically expressing APEX2 in the mitochondrial matrix, allowing for tissue-specific mitochondrial proteomic research and drug target protein identification using proximity labeling technology, where a fusion protein with a mitochondrial matrix targeting peptide and a proximity labeling enzyme (such as APEX, APEX2, or TurboID) is used to label and isolate mitochondrial proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If mitochondria are isolated using centrifugation, then mitochondrial proteins can be analyzed, but the proteins become contaminated with cytoplasmic proteins from other organelles or dead cells
Solution Approach 1:
The patent extracts and removes cytoplasmic proteins from the mitochondrial protein sample through differential centrifugation and purification steps, isolating only the mitochondrial matrix proteins for analysis. This extraction process eliminates contamination while preserving the integrity of mitochondrial proteins.
Solution Approach 2:
The patent uses an intermediary purification process involving specific enzymes and chemical reagents that selectively interact with and remove cytoplasmic proteins while leaving mitochondrial proteins unaffected. This intermediary approach enables clean separation without direct mechanical damage.
2Productivity
If conventional isolation methods are used, then proteins can be identified by mass spectrometry, but false-positive proteins are generated due to improper sample preparation
Solution Approach 1:
The patent performs preliminary purification and validation steps before mass spectrometry analysis, including differential centrifugation, protein staining, and quality control assays. These preliminary actions ensure that only genuine mitochondrial proteins are analyzed, preventing false-positive results while maintaining high identification efficiency.
Solution Approach 2:
The patent implements feedback mechanisms where intermediate results from purification steps are evaluated and used to adjust subsequent processing. Quality control measures include checking protein concentration, purity, and integrity at each stage, allowing real-time optimization to prevent false positives.
3Ease of manufacture
If density-based isolation is performed, then organelles can be separated, but fractions are contaminated with other proteins making accurate proteome analysis impossible
Solution Approach 1:
The patent segments the isolation process into multiple distinct steps: differential centrifugation to separate organelles, followed by additional purification steps specific to mitochondrial matrix proteins. This segmentation allows each step to be optimized independently, achieving both ease of manufacture and high accuracy by breaking down the complex separation into manageable stages.
Data Source
AI summary
The present invention relates to a transgenic animal in which APEX2 is specifically expressed in a mitochondrial matrix and to uses thereof. When the transgenic animal according to the present invention is used, it is possible to overcome the limitation of being susceptible to contamination with proteins derived from other organelles or other tissue cells in existing mitochondrial proteomic studies. Accordingly, mitochondrial matrix proteomic research with a high reliability is possible, tissue-specific mitochondrial matrix proteomics can easily be analyzed, and a wide range of applications are possible in basic life science research, drug development, and diagnostic research related to mitochondrial proteomics.